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BACKGROUND: The aim was to evaluate whether this gastric cancer-screening programme was effective in reducing oesophageal
cancer mortality.
METHODS: A population-based retrospective cohort study was conducted using the Korean National Cancer Screening Programme
(NCSP) database. The study cohort comprised 16,969 oesophageal cancer patients who had been diagnosed in 2007–2014. We
analysed the association between the history of NSCP for gastric cancer and oesophageal cancer mortality.
RESULTS: Compared with never-screened subjects, ever-screened subjects had an overall HR for oesophageal cancer mortality of
0.647 (95% CI, 0.617–0.679). According to the time interval since screening, the HRs of death were 0.731 (95% CI, 0.667–0.801) for
6–11 months, 0.635 (95% CI, 0.594–0.679) for 12–23 months, 0.564 (95% CI, 0.522–0.610) for 24–35 months and 0.742 (95% CI,
0.679–0.810) for ≥36 months. According to the last screening modality, the HRs of death were 0.497 (95% CI, 0.464–0.531) for upper
endoscopy, and 0.792 (95% CI, 0.749–0.838) for UGIS. Upper endoscopy reduced the mortality consistently in all age groups over
50 years, whereas UGIS could not.
CONCLUSION: The NCSP for gastric cancer was effective in reducing the mortality of oesophageal cancer, and upper endoscopy
was superior to UGIS.
British Journal of Cancer (2020) 123:480–486; https://doi.org/10.1038/s41416-020-0883-x
BACKGROUND
Oesophageal cancer (EC) is the eighth most common cancer and
the sixth leading cause of cancer-related deaths worldwide.1 In
Korea, EC is the tenth most common cause of cancer-related
death.2 Although the prognosis of EC is considered quite poor
because of rapid growth and early metastasis, the survival rate is
dependent on the stage: the 5-year survival rate of early-stage EC
has been reported to be ~60–80%, compared with a 1-year
survival rate of <20% in unresectable or metastatic EC at time of
diagnosis.3,4 Thus, early detection of EC is very important to
improve prognosis. However, there are no global screening
recommendations for EC. In particular, nationwide screening
recommendations are difficult in nations with a low incidence of
EC, like Korea.
In Korea, the National Cancer Screening Programme (NCSP) for
gastric cancer was launched in 1999 to provide gastric cancer
screening for individuals aged ≥40 years.5,6 The NCSP recom-
mends biennial gastric cancer screening for men and women
aged 40 years or older, by either upper gastrointestinal series
(UGIS) or upper endoscopy.7 Despite having several limitations,8
the NCSP was recently reported to be effective in reducing gastric
cancer mortality.6 According to that study, however, the effect of
NCSP on reduction of gastric cancer mortality was observed only
in those 40–74 years, not ≥75 years.
Examinations for gastric cancer can also detect EC, so screening
programmes for gastric cancer can affect the prognosis of EC.
However, no study has evaluated whether screening programmes
for gastric cancer help to improve the prognosis of EC. Therefore,
we evaluated whether the NCSP for gastric cancer can be effective
to reduce EC mortality. We hypothesise that the current gastric
cancer-screening programme is valid for improving the prognosis
of EC as well as gastric cancer.
METHODS
Study population
This population-based retrospective cohort study was conducted
using data maintained by the NCSP since 2002 in Korea.
Participants in the NCSP can choose to undergo either upper
endoscopy or UGIS, depending on their personal preference. In
2002, National Health Insurance (NHI) beneficiaries in the lower
20% income bracket were eligible for the programme. In 2003 and
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2004, the NCSP expanded its target population to the lower 30%
income bracket, and in 2005, NHI beneficiaries in the lower 50%
bracket were deemed eligible.
The study cohort consisted of 16,969 EC patients who had been
diagnosed in 2007–2014. EC was defined using the International
Classification of Diseases, 10th revision (ICD-10) codes (C15.0–15.5,
C15.8 and C15.9). To assess the validity of defining EC using ICD-
10, the data with codes (C15.0–15.5, C15.8 and C15.9) were
extracted and analysed at Gangnam Severance Hospital between
2007 and 2014. All subjects with those codes (C15.0–15.5, C15.8
and C15.9) were considered to have EC. Furthermore, the number
of subjects with EC defined using ICD-10 in our study was similar
to that of the Korea Central Cancer Registry.9 According to that
report,9 there were 2382 new cases of EC in 2013, which is similar
to our data (2281 in 2013, Table 1).
To avoid confounding effects on mortality by pre-existing or
combined other cancer, individuals with any diagnosis of cancer
were excluded. Because the linkage with the database of the
Korea Central Cancer Registry was unavailable due to strict privacy
control law, the stage of EC could not be analysed. Instead, stent
insertion was examined using the Korean National Health
Insurance Services (NHIS) billing claims database for differentiat-
ing advanced EC.10,11
This study collected the data from the NCSP database, which
included information on the participants’ demographic features.
We collected the data from the National Health Insurance Service
(NHIS). The need for informed consent for this specific study was
waived by IRB review because the KNCSP database is quite large.
With permission from the Ministry of Health and Welfare, the
investigators used data maintained and deidentified by the NHIS.
This study was approved by the Institutional Review Board of
Gangnam Severance Hospital, Korea (Institutional Review Board
no. 3-2017-0362).
Outcomes
The primary outcome of this study was EC mortality. Information
concerning the cause of death was obtained by linking the NCSP
database and the death certificate database from Statistics Korea.
EC mortality is defined as EC-specific death that the cause of death
is EC. Furthermore, chronic diseases such as diabetes mellitus
(DM), heart disease, cerebrovascular disease, liver disease,
pulmonary disease or chronic kidney disease were adjusted using
ICD-10 codes.
In this study, 16,969 EC patients diagnosed in 2007–2014 were
followed until December 2015. During follow-up period, the
association between the history of NSCP for gastric cancer and EC
mortality was analysed.
Exposure to screening test
In this study, data on exposure to the screening test were
collected from the KNCSP database. The exposure to screening
test was investigated from January 2002 to the date 6 months
prior to being diagnosed with EC. Testing that within 6 months of
being diagnosed with EC was not considered as exposure to the
screening test because such tests had a diagnostic role rather than
a screening role for EC. We defined ever-screened as having had at
least one gastric cancer-screening test including upper endoscopy
or UGIS during that period. The number of screening tests during
the 5 years before diagnosis was evaluated. The time interval since
the last screening was categorised as follows: 6–11 months,
12–23 months, 24–35 months and ≥36 months.
Statistical analysis
The baseline data are expressed as means (SD) or numbers (%).
The mortality rate (MR) per 1000 was measured considering the
follow-up duration. To investigate the effects of gastric cancer-
screening test on reducing mortality from EC, hazard ratios (HRs)
with 95% confidence intervals (CIs) for dying from EC were
obtained via Cox proportional-hazards regression analysis. We
conducted subgroup analyses stratified by age, sex, income level,
the last screening method, stent insertion and time interval since
screening. HRs were adjusted by age, sex and underlying chronic
disease using multiple Cox proportional hazard regression
Table 1. Baseline characteristics of study cohort.
Variables N (%)















Body mass index (BMI, mean ± SD) 22.85 ± 3.09
Waist circumference (mean ± SD) 82.71 ± 8.41
Comorbidity
Diabetes mellitus 6091 (35.89)
Heart disease 9467 (55.79)
Cerebrovascular disease 4477 (26.38)
Liver disease 5455 (32.15)
Pulmonary disease 8891 (52.40)





Proton pump inhibitor use 7043 (86.54)
Ever-screened 8666 (51.07)
Number of screening during 5 years before diagnosis
None 8303 (48.93)
1 4542 (26.77)
≥2 or over 4124 (24.30)





≥36 or over 1557 (9.18)
The last screening method
None 8303 (48.93)
Upper endoscopy 4190 (24.69)
Upper gastrointestinal series 4476 (26.38)
Combined precancerous lesions
Low-grade dysplasia, oesophagus 682 (8.38)
High-grade dysplasia, oesophagus 251 (3.08)





Concomitant chemo-radiation 1932 (23.74)
Stent insertion 921 (5.43)
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analysis. To compare mortality reduction between upper endo-
scopy and UGIS, Bonferroni post hoc analysis was used.
Survival curves were estimated using the Kaplan–Meier analysis
and log-rank test. P-values<0.05 were considered statistically
significant, except Bonferroni post hoc analysis. The significant
P-value for Bonferroni post hoc analysis was 0.05/3. All statistical
analyses were conducted using SAS version 9.4 (SAS Institute,
Cary, NC).
RESULTS
Baseline characteristics of study cohort
Table 1 shows the baseline characteristics of the study cohort.
Approximately half of the subjects (48.93%) had never been
screened. Among ever-screened subjects, upper endoscopy or UGIS
was similarly selected as the last screening method before diagnosis
of EC. A total of 921 (5.43%) patients underwent stent insertion.
Association between receipt of screening and mortality
Among all 16,969 EC patients, 6729 (39.65%) patients had EC-specific
death during the follow-up period. The HRs of mortality according to
the baseline characteristics including screening features are provided
in Table 2. Older age, male, lower income level and stent insertion
status were significantly associated with mortality.
When analysing the survival rate among never-screening, upper
endoscopy and UGIS, upper endoscopy showed a survival benefit
compared with never-screening, not UGIS (Supplement 1). Table 3
shows results of the multivariate analysis of the association
between receipt of screening test and mortality. In Table 3, model
2 was adjusted by age, sex, income level and underlying chronic
diseases. Compared with subjects who had never been screened,
the overall HR for dying from EC among ever-screened subjects
was 0.647 (95% CI, 0.617–0.679). According to the last screening
modality, the HRs of death from EC were 0.497 (95% CI,
0.464–0.531) for upper endoscopy and 0.792 (95% CI,
0.749–0.838) for UGIS. The difference in HRs between upper
endoscopy and UGIS were statistically significant (using Bonferroni
method). Compared with never-screened individuals, those
screened last by upper endoscopy consistently showed lower
HRs for all age groups over 50 years; in contrast, UGIS did not
(Fig. 1). As the number of screening tests performed per subject
increased, the HRs of death from EC decreased: 0.703 (95% CI,
0.663–0.744) and 0.588 (95% CI, 0.552–0.626) for one and ≥2
times, respectively (Table 3).
According to the time interval since screening, the HRs of death
from EC were 0.731 (95% CI, 0.667–0.801) for 6–11 months, 0.635
(95% CI, 0.594–0.679) for 12–23 months, 0.564 (95% CI, 0.522–0.610)
for 24–35 months, and 0.742 (95% CI, 0.679–0.810) for ≥36 months
Table 2. HRs and 95% CIs for the mortality rate according to baseline characteristics.
N Death Duration MR (per 1000) Crude HR (95% CI) P
Age (year) <0.0001
<65 7610 2682 22,847.65 117.3863 1
65–74 6399 2590 17,418.38 148.6935 1.233 (1.168–1.301)
≥75 2960 1457 5560.98 262.004 1.956 (1.835–2.085)
Sex <0.0001
Male 15136 6230 40,391.13 154.2418 1
Female 1833 499 5435.88 91.7975 0.634 (0.579–0.695)
Income level <0.0001
High 4203 1527 11,639.94 131.1862 1
Middle 7526 2939 20,957.18 140.2383 1.075 (1.010–1.143)
Low 5240 2263 13,229.88 171.0522 1.274 (1.194–1.359)
Ever-screened <0.0001
No 8303 3718 21,981.27 169.144 1
Yes 8666 3011 23,845.73 126.27 0.708 (0.675–0.743)
Number of screening during 5 years before diagnosis
None 8303 3718 21,981.27 169.44 1 <0.0001
1 4542 1677 12,958.37 129.4144 0.748 (0.706–0.792)
≥2 or over 4124 1334 10,887.36 122.5274 0.665 (0.624–0.708)
Time interval since the last screening (month) <0.0001
Never-screened 8303 3718 21,981.27 169.144 1
6–11 1376 526 3836.04 137.1205 0.798 (0.728–0.874)
12–23 3273 1144 9340.12 122.4823 0.694 (0.650–0.742)
24–35 2460 765 6787.04 112.7148 0.623 (0.576–0.673)
≥36 or over 1557 576 3882.53 148.357 0.806 (0.739–0.880)
The last screening method <0.0001
Never-screened 8303 3718 21,981.27 169.144 1
Upper endoscopy 4190 1108 11,839.38 93.586 0.515 (0.481–0.550)
Upper gastrointestinal series 4476 1903 12,006.35 158.4994 0.907 (0.858–0.959)
Stent insertion
No 16,048 6048 44,977.42 134.4675 1 <0.0001
Stent insertion 921 681 849.59 801.5666 5.211 (4.806–5.650)
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Table 3. Association between receipt of screening test and mortality.
N Death Duration MR (per 1000) Model 1 P Model 2 P
Ever-screened <0.0001 <0.0001
No 8303 3718 21,981.27 169.144 1 1




Number of screening during 5 years before
diagnosis
<0.0001 <0.0001
None 8303 3718 21,981.27 169.44 1 1








Time interval since the last screening (month) <0.0001 <0.0001
No 8303 3718 21,981.27 169.144 1 1
















The last screening methoda <0.0001 <0.0001
Never-screened 8303 3718 21,981.27 169.144 1 1









Model 2: adjusted by age, sex, income level and underlying chronic disease, including diabetes mellitus, heart disease, cerebrovascular disease, liver disease,
pulmonary disease or chronic kidney disease.
aWhen multiple comparison test using Bonferroni method was performed, all P-values of ‘never-screened vs. upper endoscopy’, ‘never-screened vs. upper



















40–44 45–49 50–54 55–59 60–64
Age group (year)
65–69 70–74 75–79 80–84 85–
Fig. 1 Association between screening and oesophageal cancer mortality according to the last screening modality since the last screening
in comparison with never-screened individuals. Total indicates upper endoscopy or UGIS as the last screening modality. EGD upper
endoscopy, UGIS upper gastrointestinal series.
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(Table 3). This indicates that the current biennial screening in
KNCSP is effective to reduce the mortality of EC subjects.
Table 4 shows the association between receipt of screening test
and mortality, for individuals <75 years and ≥75 years. Compared
with never-screened subjects, individuals ≥75 years had, which is
different from a previous report about gastric cancer.6
DISCUSSION
According to our study, the current NCSP for gastric cancer was
effective in reducing the mortality of EC, and upper endoscopy
was superior to UGIS.
In our cohort of EC, the portion of ever-screened subjects was
~50%, which is similar to that of general population.12,13 In this
study, the rate of upper endoscopy and UGIS performed as the last
screening was similar. This result contradicts results of previous
studies indicating that the portion of patients screened by upper
endoscopy is increasing.5,14 A likely reason for this contradictory
result is that we could not consider the opportunistic screening by
individuals; thus, subjects who underwent UGIS as part of their
NCSP screening might be undergone upper endoscopy as
opportunistic screening. This may overestimate the effect of UGIS
in NCSP on the reduction of EC mortality.
Our study showed that the NCSP for gastric cancer can reduce EC
mortality by 35.3%. Furthermore, according to the last screening
modality, the HR of death from EC for upper endoscopy was
significantly lower than that for UGIS (0.497 vs. 0.792). Univariate
analysis showed that upper endoscopy screening, but not UGIS, was
beneficial to survival compared with no-screening. However, multi-
variate analysis showed that UGIS had an effect on reducing EC
mortality, but this effect was significantly weaker than that of upper
endoscopy. Furthermore, upper endoscopy showed a consistent
reduction of EC mortality in all age groups over 50 years, whereas
UGIS did not. Thus, to reduce EC mortality, upper endoscopy can be
more effective than UGIS in NCSP for gastric cancer.
A recent study concerning the effectiveness of NCSP showed
that gastric cancer mortality was reduced only in individuals
40–74 years, not 75 years or over.6 However, in our study, upper
endoscopy consistently reduced EC mortality in all age groups
since 50 years. A comparison of individuals <75 and ≥75-years old
showed that the national cancer screening within 36 months
could also reduce EC mortality in individuals ≥75 years. In fact,
17.4% of the EC patients were ≥75 years old in our cohort. This
indicates that the national cancer screening can be also effective
in reducing EC mortality in the elderly.
According to our data, all time intervals since the last screening
(6–11, 12–23, 24–35, 36 months over) could reduce EC mortality
compared with never-screened. That is, this suggested that
screening itself may be important to decrease mortality in EC,
similar to the previous China study.15 The previous study showed
one-time endoscopic screening and then intervention including
endoscopic resection or coagulation for dysplasia/early cancer
significantly reduced mortality caused by EC. Precancerous lesions
such as dysplasia was observed in about 11.9%. However,
endoscopic submucosal dissection was covered by insurance since
November 2018 in Korea, so we could not analyse whether the
lesions were resected or not. Thus, the preventive effect of EC by
intervention of precursor lesions was not evaluated. In our study,
risk reduction of EC mortality was not correlated with degree of
time intervals since the last screening, that is, the risk of EC
mortality was not decreased according to shorter time intervals
since the last screening. The reason was probably due to
misclassification of upper endoscopy and UGIS as screening tests.
That is, those with symptoms or signs suspicious for EC could have
undergone screening test. To prevent misclassification in our study,
testing that within 6 months of being diagnosed with EC was not
considered as exposure to the screening test because such tests
had a diagnostic role rather than a screening role for EC. In spite of
that, 6–11 months since the last screening showed higher HR for
dying from EC than 12–35 months since the last screening.
Oesophageal squamous cell carcinoma and adenocarcinoma
are the two most common histopathological types of EC.
Oesophageal squamous cell carcinoma remains the dominant
type of EC worldwide, particular in East Asia, including Korea.16,17
The percentage of oesophageal adenocarcinoma amongst oeso-
phageal malignancies was as low as 1–4% in Korea in a previous
study.18 Endoscopy is known to be useful in screening for Barrett-
related adenocarcinomas worldwide, but the usefulness of
screening for squamous cell carcinoma is not yet known.18,19 For
Barrett’s oesophagus and early adenocarcinoma, active endo-
scopic screening with adequate surveillance is recommended for
people with chronic reflux symptoms and at least one risk factor
for oesophageal adenocarcinoma, depending on the lesion found
on the index endoscopy and pathology.18
However, there is no standardised screening programme to
detect precancerous lesions such as squamous dysplasia of
squamous cell carcinoma.18,20 In Japan, controversy exists
concerning whether precancerous lesions should be actively
detected by screening.18 In China, however, which has a high
incidence of EC, endoscopic screening of EC is considered to be
cost-effective in high-risk areas.21 In China, the following two key
measures to combat oesophageal squamous cell carcinoma were
recommended as cost-effective programmes, considering the
acceptance of the population and the distribution of wealth in
different regions:18,21 (1) screening once beginning at the age of
50, following up 5 years after detecting low-grade dysplasia and 3
years after intermediate-grade dysplasia, for areas with limited
access to healthcare, impoverished areas and areas in which it is
difficult to track the target population economy;18,21 and (2)
screening three times beginning at the age of 40, and monitoring
low-grade dysplasia and intermediate-grade dysplasia as above,
for areas with appropriate access to healthcare, and economies
that are more advanced and areas in which there are good
monitoring programmes of the target population.18,21
In Korea, the incidence of EC is increasing, as shown in our study
and similar to a previous study.9 However, the incidence of EC is
not high, so it is difficult to determine the necessity or strategy of
a screening programme for EC like in China. However, a screening
strategy should be investigated in the future for high-risk groups
such as old age, smoking or patients with head and neck cancer.
Instead of screening programme for EC, there is nationwide
screening programme for gastric cancer in Korea. Because
examinations for gastric cancer can also detect EC, screening
programmes for gastric cancer could be effective in reducing EC
mortality. If possible, the nationwide screening programme for
gastric cancer should be re-evaluated for its effectiveness to reduce
the mortality of both gastric cancer and EC. According to our data,
the current NCSP of biennial upper endoscopic screening for gastric
cancer is also effective in reducing the mortality of EC, especially for
≥50-year-old individuals. This suggests that NCSP, which targets
gastric cancer, can be expected to have an additional survival
benefit for not only gastric cancer but also EC. However, NCSP was
designed for gastric cancer, but not for EC. Thus, screening
programme for EC should be investigated in the future. In addition,
a cost-analysis for person-life saved by enrolment in this screening
programme is important to confirm the screening effect for EC.
Thus, a cost-analysis should be performed in the future.
This study had several limitations. First was the self-selection
bias. The participants in the NCSP might be overrepresented by
healthy or health-conscious individuals.6 This could have led to an
overestimation of the effectiveness of the screening programme.
In our data, the HR of death from EC of UGIS was lower than that
of no-screening. Considering the method itself, UGIS is a less
effective method to examine the oesophagus. This result may be
influenced by the fact that participants in the NCSP might be more
health conscious. The self-selection bias can be related to
Association between the National Cancer Screening Programme (NSCP) for. . .
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detection bias in our study. The subjects with chronic diseases
may be different from others in terms of health-consciousness or
hospital visits. When adjusted by age, sex, income and underlying
chronic diseases, the effect of screening on reducing EC mortality
was also observed in Tables 3 and 4. Therefore, the self-selection
and detection bias may not affect significantly our results. The
length bias is one of the issues for screening studies. However, the
length bias can be more related to slowly growing tumours, so it
may not be important for EC.
Second was the lead time bias. Ever-screened patients may
seem to be surviving longer solely because they are diagnosed
earlier, not screening-test effect. However, according to our data,
the survival curves showed a plateau at almost 70% for EGD,
whereas almost 40% for UGIS. These survival curves mean that the
favourable results are not solely due to lead time bias.
Third, opportunistic screening in Korea was not considered in
this study. Considering opportunistic screening, the effect of upper
endoscopy on reducing EC mortality would have been greater.
Fourth limitation is that a lack of data regarding the specific
details such as specific symptoms, such as oesophageal reflux,
Helicobacter pylori status, histologic differentiation of EC or cancer
stage, because we collected the data from the NHIS with permission
from the Ministry of Health and Welfare. In addition, it is impossible
to link the NHIS database and the National Cancer Registry because
of the Personal Information Protection Act in Korea.
In conclusion, the current NCSP for gastric cancer was effective
in reducing the mortality of EC, and upper endoscopy was
superior to UGIS. Thus, we can improve the prognosis of EC
through the nationwide upper endoscopic screening policy for
gastric cancer. This may suggest that endoscopic screening for EC
can be reasonable in high-risk subjects.
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